Semaglutide vs Tirzepatide (Ozempic vs Mounjaro)
Semaglutide and tirzepatide are the two dominant obesity and type-2 diabetes peptide drugs of the 2020s. Both are injectable peptides taken weekly, both work through incretin biology, and both have transformed the pharmaceutical industry — but they differ in mechanism (semaglutide is a GLP-1 receptor agonist only; tirzepatide is a dual GLP-1/GIP agonist), efficacy (tirzepatide produces greater weight loss head-to-head), and evidence base (semaglutide has larger cardiovascular outcomes data). As of 2026, both are blockbuster franchises with Novo Nordisk and Eli Lilly together accounting for roughly $75 billion in annual obesity and diabetes revenue.
Last updated: April 8, 2026
Semaglutide (Ozempic / Wegovy)
A GLP-1 receptor agonist peptide developed by Novo Nordisk. Modified from native GLP-1 with a fatty acid chain that enables albumin binding and a ~1-week half-life. Approved for type 2 diabetes (Ozempic, 2017), chronic weight management (Wegovy, 2021), and cardiovascular risk reduction in overweight adults (2024). Also available orally as Rybelsus.
Tirzepatide (Mounjaro / Zepbound)
A dual GLP-1 and GIP receptor agonist peptide developed by Eli Lilly. The first-in-class 'twincretin' — a single peptide engineered to activate both incretin pathways simultaneously for synergistic effects on weight loss and glucose control. Approved for type 2 diabetes (Mounjaro, 2022) and obesity (Zepbound, 2023).
Key Specifications
| Feature | Semaglutide (Ozempic / Wegovy) | Tirzepatide (Mounjaro / Zepbound) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | GLP-1 + GIP dual receptor agonist |
| Structure | GLP-1 analog with Aib substitution + fatty acid chain | Engineered 39-aa peptide with C20 fatty diacid |
| Half-life | ~7 days (once-weekly dosing) | ~5 days (once-weekly dosing) |
| Average weight loss (68 weeks) | ~15% of body weight (STEP trials) | — |
| HbA1c reduction | ~1.5–1.8% | ~2.0–2.4% |
| Cardiovascular benefit | 20% MACE reduction (SELECT, 2023) | SURPASS-CVOT pending; surrogate markers favorable |
| FDA approvals | Type 2 diabetes, obesity, CV risk reduction | Type 2 diabetes, obesity, obstructive sleep apnea |
| Manufacturer | Novo Nordisk (NVO) | Eli Lilly (LLY) |
| Brand names | Ozempic, Wegovy, Rybelsus (oral) | Mounjaro, Zepbound |
| 2025 sales | ~$40B (combined) | ~$35B (combined) |
| Average weight loss (72 weeks) | — | ~20.9% at highest dose (SURMOUNT-1) |
Semaglutide (Ozempic / Wegovy)
Advantages
- Strongest cardiovascular outcomes data — SELECT trial showed 20% reduction in major adverse cardiovascular events
- FDA-approved for cardiovascular risk reduction in overweight/obese adults (2024)
- Kidney protection data from FLOW trial (24% reduction in kidney disease progression)
- Emerging evidence for Alzheimer's (EVOKE trial ongoing) and addiction outcomes
- Oral formulation available (Rybelsus) — the first oral GLP-1 peptide
- Longer real-world safety record (launched 2017 for diabetes)
Limitations
- Less weight loss than tirzepatide head-to-head in SURMOUNT-5 (~15% vs ~20%)
- Persistent supply constraints throughout 2023–2025
- GI side effects (nausea, vomiting, constipation) common, especially during dose escalation
- US list price ~$1,350/month without insurance
- Rebound weight gain after discontinuation
Tirzepatide (Mounjaro / Zepbound)
Advantages
- Greater weight loss than semaglutide head-to-head — SURMOUNT-5 showed ~20% vs ~15% (2024)
- Superior HbA1c reduction (~2.0–2.4%) in type 2 diabetes
- Dual GLP-1/GIP mechanism may improve tolerability at high doses
- Growing evidence for obstructive sleep apnea (SURMOUNT-OSA, 2024 FDA approval)
- MASH/NASH data from SYNERGY-NASH trial
- Lilly's manufacturing scale-up has improved supply vs Novo
Limitations
- Shorter clinical track record (launched 2022)
- Cardiovascular outcomes trial (SURPASS-CVOT) results not yet mature
- Similar GI side effect profile to semaglutide
- US list price ~$1,060/month without insurance
- No oral formulation yet (orforglipron is a small molecule, not peptide)
The Verdict
For raw weight loss, tirzepatide wins — SURMOUNT-5 confirmed superiority head-to-head. For cardiovascular risk reduction in patients who already have heart disease or multiple CV risk factors, semaglutide's SELECT trial gives it a decisive evidence edge and an FDA indication tirzepatide doesn't yet have. For patients prioritizing an oral option, only Rybelsus (oral semaglutide) is a true oral peptide. For most new prescriptions purely targeting obesity in 2026, tirzepatide has become the default choice where available. Both drugs represent a once-in-a-generation shift in how we treat metabolic disease — the choice between them is now genuinely about which dimension of the evidence base matters most to the individual patient.